Back to search
FDAFDA · Food and drugs·Recall number D-0110-2027

Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10

Published November 4, 2026 · Recall initiated: October 6, 2026

Summary

FDA records drug Class II recall D-0110-2027, published November 4, 2026 and initiated October 6, 2026. Recalling firm: Brandywine Pharmaceuticals, LLC; Status: Ongoing; Reported quantity: 1,620 100-count bottles; Lot: Lot: 405617, Expiry: 03/31/2028. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Brandywine Pharmaceuticals, LLC
Distributor
Nationwide within U.S
Lot
Lot: 405617, Expiry: 03/31/2028
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10 recalled?

Yes. FDA published recall D-0110-2027 on November 4, 2026. Reported hazard: CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit